There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it? “Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s. The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest. “Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,426 crores in the month of August 2016 clocking a strong 18% growth over same period last year (SPLY). This was the second consecutive month where the IPM crossed the 10,000 crore mark.

Lower prices, discounts, convenience of ordering and home delivery are some of the benefits for consumers with e-pharmacies. The anonymity of the internet encourages patients to seek information about medicines that they would otherwise avoid. Mental health is one area where the consumers wish to maintain confidentiality and opt for online consultation and medication.

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma? My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well. I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience.  I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.

Here is an analytical blog comparing the IQVIA MFR...

The latest PharmaTrac report for December 2025 offers a...

Zydus’ ZYCUBO May Be the Proof Point the Industry...

For more than fifty years, the MRI industry treated...

The Telangana Drugs Control Administration’s stop-use notice on a...

Here is an analytical blog comparing the IQVIA MFR...

The latest PharmaTrac report for December 2025 offers a...

Zydus’ ZYCUBO May Be the Proof Point the Industry...

For more than fifty years, the MRI industry treated...

The Telangana Drugs Control Administration’s stop-use notice on a...

Here is an analytical blog comparing the IQVIA MFR...

The latest PharmaTrac report for December 2025 offers a...

Zydus’ ZYCUBO May Be the Proof Point the Industry...

For more than fifty years, the MRI industry treated...

The Telangana Drugs Control Administration’s stop-use notice on a...

Here is an analytical blog comparing the IQVIA MFR...

The latest PharmaTrac report for December 2025 offers a...

Zydus’ ZYCUBO May Be the Proof Point the Industry...

For more than fifty years, the MRI industry treated...

The Telangana Drugs Control Administration’s stop-use notice on a...